LU92826I2 - Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone - Google Patents

Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone Download PDF

Info

Publication number
LU92826I2
LU92826I2 LU92826C LU92826C LU92826I2 LU 92826 I2 LU92826 I2 LU 92826I2 LU 92826 C LU92826 C LU 92826C LU 92826 C LU92826 C LU 92826C LU 92826 I2 LU92826 I2 LU 92826I2
Authority
LU
Luxembourg
Prior art keywords
lubip
rostone
lubiprostone
amides
esters
Prior art date
Application number
LU92826C
Other languages
English (en)
French (fr)
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92826(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of LU92826I2 publication Critical patent/LU92826I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
LU92826C 2001-11-14 2015-09-11 Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone LU92826I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
LU92826I2 true LU92826I2 (fr) 2015-11-24

Family

ID=23293447

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92826C LU92826I2 (fr) 2001-11-14 2015-09-11 Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone

Country Status (15)

Country Link
US (3) US8097653B2 (ja)
EP (2) EP2298314B1 (ja)
JP (2) JP4852229B2 (ja)
AR (3) AR037524A1 (ja)
AT (1) ATE522218T1 (ja)
BR (1) BR0214075A (ja)
CA (1) CA2464420C (ja)
CY (1) CY1115856T1 (ja)
DK (2) DK2298314T3 (ja)
ES (2) ES2524369T3 (ja)
HK (1) HK1155649A1 (ja)
LU (1) LU92826I2 (ja)
PT (2) PT1443938E (ja)
TW (1) TWI331920B (ja)
WO (1) WO2003041716A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
CN1753680B (zh) * 2002-12-27 2010-12-08 苏坎波公司 用于治疗腹部不适的前列腺素衍生物
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
AU2006234632B2 (en) * 2005-04-12 2011-10-27 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
CA2637274C (en) * 2006-01-24 2013-06-04 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
NZ570190A (en) 2006-01-24 2011-03-31 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
ATE174221T1 (de) 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
ATE141794T1 (de) * 1991-03-14 1996-09-15 R Tech Ueno Ltd Stimulierung von wundheilung mit 15-keto- prostaglandinverbindungen
PH31171A (en) * 1992-02-04 1998-03-20 Esai Co Ltd Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
DE69714698T2 (de) * 1996-06-10 2002-12-05 Sucampo Ag, Zug Endothelin-antagonisten
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
NZ336960A (en) * 1997-11-28 2001-02-23 R Tech Ueno Ltd Use of 15-keto-prostaglandin E compounds for the preparation of medicaments for use as endothelin antagonists
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
PT1220849E (pt) 1999-10-15 2004-10-29 Sucampo Ag Composicao de compostos biciclicos e metodo para a sua estabilizacao
DE60139002D1 (de) 2000-04-06 2009-07-30 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR035242A1 (es) 2001-05-18 2004-05-05 Sucampo Ag Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
AU2002330747B2 (en) * 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
CN1753680B (zh) * 2002-12-27 2010-12-08 苏坎波公司 用于治疗腹部不适的前列腺素衍生物

Also Published As

Publication number Publication date
CY1115856T1 (el) 2017-01-25
ATE522218T1 (de) 2011-09-15
US8097653B2 (en) 2012-01-17
AR037524A1 (es) 2004-11-17
CA2464420C (en) 2011-12-13
US8389542B2 (en) 2013-03-05
US20030119898A1 (en) 2003-06-26
AR098997A2 (es) 2016-06-22
ES2524369T3 (es) 2014-12-05
TWI331920B (en) 2010-10-21
WO2003041716A1 (en) 2003-05-22
US20120088824A1 (en) 2012-04-12
JP2011201905A (ja) 2011-10-13
CA2464420A1 (en) 2003-05-22
ES2368729T3 (es) 2011-11-21
DK1443938T3 (da) 2011-09-26
JP4852229B2 (ja) 2012-01-11
HK1155649A1 (en) 2012-05-25
PT2298314E (pt) 2014-12-03
PT1443938E (pt) 2011-09-27
EP2298314B1 (en) 2014-09-03
BR0214075A (pt) 2004-09-28
EP2298314A1 (en) 2011-03-23
AR117404A2 (es) 2021-08-04
EP1443938A1 (en) 2004-08-11
TW200300091A (en) 2003-05-16
US20130143958A1 (en) 2013-06-06
DK2298314T3 (en) 2014-12-01
EP1443938B1 (en) 2011-08-31
JP2005513014A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
LU92826I2 (fr) Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone
FR2828408B1 (fr) Procede de formation d'implant
DE10085137T1 (de) Chirurgischer Sensor
PL364223A1 (en) Pharmaceutical salts
DE60126038D1 (de) Chirurgisches Ultraschallsystem
GB0101990D0 (en) Surgical system
ZA200403373B (en) Novel benzophenone derivatives or salts thereof
NO20040198L (no) Dolastatin 10 derivater
IT1317741B1 (it) Metodo per la preparazione di 5-cianoftalide.
IT1319251B1 (it) Metodo per la preparazione di 5-carbossiftalide.
FR2833596B1 (fr) Procede de preparation de derives d'echinocandine
ITMI20011503A0 (it) Procedimeno per sterilizzare oggetti
FR2818979B1 (fr) Procede de preparation d'imidaclopride
DE60029273D1 (de) Titan-Tinoxidfilme
MA27240A1 (fr) Derives d'imidazoquinoleine
GB2394899B (en) Ophtalmic tissue barrier
MXPA03003346A (es) Metodo para la purificacion de pravastatina o una sal farmacologicamente aceptable de la misma.
ITRM20010332A0 (it) Vaccini a subunita' e procedimenti per la loro produzione.
ITMI992457A0 (it) Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidrois ochinolin-3-carbossiammide
ITRM990762A0 (it) Procedimento per la preparazione di filati ondee o compensina.
ITMI20000810A0 (it) Procedimento per la preparazione di 5'-acetilstavudina
MA25828A1 (fr) Procede de preparation d'oligomeres de galactomannanes
ITMI20012131A0 (it) Procedimento per la preparazione di alo-benzonitrili
ITMI20002173A0 (it) Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-treraidroisochinolin-3-carbossiammide
ITMI20011344A0 (it) Procedimento per la preparazione di 1,3-diossolan-2-oni